Ware et al Chan HS, Correia JA, MacLeod SM. 1987. Nabilone versus prochlorpera- zine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics, 79:946–52. Crawford SM, Buckman R. 1986. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother, 3:39–42. Croxford JL. 2003. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs, 17:179–202. Cunningham, D, Bradley, CJ, Forrest, GJ, et al. 1988. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclo- pramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol, 24:685–9. Daut RL, Cleeland CS. 1982. The prevalence and severity of pain in cancer. Cancer, 50:1913–18. Diana MA, Mart A. 2004. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Phar- macol, 142:9–19. Einhorn LH, Nagy C, Furnas B, Williams SD. 1981. Nabilone: An effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharma- col, 21(suppl):64–69. Fabre LF, McLendon D. 1981. The efﬁcacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol, 21:377S. Freund TF, Katona I, Piomelli D. 2003. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev, 83:1017–66. Fride E, Bregman T, Kirkham TC. 2005. Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Exp Biol Med, 230:225–34. Gralla RJ, de Wit R, Herrstedt J, et al. 2005. Antiemetic efﬁcacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a cor- ticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer, 104:864–8. Grunberg SM. 1989. Advances in the management of nausea and vomit- ing induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev, 3:216–21. Herman TS, Einhorn LH, Jones SE, et al. 1979. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med, 300:1295–7. Herman TS, Jones SE, Dean J, et al. 1977. Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomedicine, 27:331–4. Hickok JT, Roscoe JA, Morrow GR, et al. 2003. Nausea and emesis remain signiﬁcant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer, 97:2880–6. Hornby PJ. 2001. Central neurocircuitry associated with emesis. Am J Med, 111(suppl 8A):106–12. Howlett AC, Barth F, Bonner TI, et al. 2002. International union of phar- macology. XXVII. Classiﬁcation of cannabinoid receptors. Pharmacol Rev, 54:161–202. Jenns K.1994. Importance of nausea. Cancer Nurs, 17:488–93. Kalant H. 2001. Medicinal use of cannabis: history and current status. Pain Res Manage, 6:80–91. Kris MG, Hesketh PJ, Somerﬁeld MR, et al. 2006. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol, 24:2932–47. Lee J, Dibble SL, Pickett M, et al. 2005. Chemotherapy-induced nausea/ vomiting and functional status in women treated for breast cancer. Cancer Nurs, 28:249–55. Lemberger L, Rowe H. 1975. Clinical pharmacology of nabilone, a can- nabinol derivative. Clin Pharm Ther, 18:720–26. Limebeer CL, Hall G, Parker LA. 2006. Exposure to a lithium-paired context elicits gapin in rats: A model of anticipatory nausea. Physiol Behav, 88:398–403. Lynch ME. 2005. Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manage, 10(suppl A):7A-14A. Mack A, Joy J. 2001. Marijuana as Medicine. Washington, DC: National Academy Press. Malik IA, Khan WA, Qazilbash M et al. 1995. Clinical efﬁcacy of lorazepam in prophylaxis of anticipatory acute and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol, 18:170–5. Martin BR, Wiley JL. 2004. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol, 2:305–14; discussion 314–16. Meiri, E, Jhangiani, H, Vredenburgh, JJ, et al. 2007. Efﬁcacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin, 23:533–43. Morran C, Smith DC, Anderson DA, et al. 1979. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. BMJ, 1:1323–4. Morrow GR, Roscoe JA, Kirshner JJ, et al. 1998. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer, 6:244–7. Nahas G, Harvey DJ, Sutin K, et al. 2002. A molecular basis of the therapeu- tic and psychoactive properties of cannabis (D9-tetrahydrocannabinol). Prog Neuro-Psychopharmacol Biol Psychiatry, 26:721–30. National Cancer Institute. 2006. [online] Accessed 9 September 2006. URL: http://www.meds.com/pdq/supportive_pro.html. National Comprehensive Cancer Network. 2006. Clinical Practice Guide- lines in Oncology. Antiemesis. v2.2006 [online]. Accessed 9 September 2006. URL: http://www.nccn.org. Navari R. 2003. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting – two new agents. J Support Oncol, 1:89–103. Niederle N, Schutte J, Schmidt CG. 1986. Crossover comparison of the antiemetic efﬁcacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr, 64:362–5. Niiranen A, Mattson K. 1985. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol, 8:336–40. Niiranen A, Mattson K. 1987. Antiemetic efﬁcacy of nabilone and dexa- methasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol, 10: 325–9. Notcutt W, Price M, Miller R, et al. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ’N of 1' studies. Anaesthesia, 59:440–52. Parker LA, Kemp SW. 2001.Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipa- tory nausea and vomiting (ANV). Neuroreport, 12:749–51. Parker LA, Kwiatkowska M, Mechoulam R. 2006. Delta-9-tetrahydrocan- nabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus muri- nus: An animal model of anticipatory nausea and vomiting. Physiol Behav, 87:66–71. Piomelli D. 2003. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci, 4:873–84. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. on behalf of the Aprepitant Protocol 054 Study Group. 2003. Addition of the neuro- kinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer, 97:3090–8. Pomeroy M, Fennelly JJ, Towers M. 1986. Prospective randomized double- blind trial of nabilone versus domperidone in the treatment of cytotoxic- induced emesis. Cancer Chemother Pharmacol, 17:285–88. Priestman TJ, Priestman SG. 1984. An initial evaluation of nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol, 35:265–6. Priestman SG, Priestman TJ, Canney PA. 1987. A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. Clin Radiol, 38:543–4. 106 Therapeutics and Clinical Risk Management 2008:4(1)